farmakokinetik
DESCRIPTION
KinetikTRANSCRIPT
![Page 1: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/1.jpg)
1
Clinical Pharmacokinetics (1)
• A fundamental hypothesis of clinical pharmacokinetics is that a relationship exists between effects of a drug and concentration of the drug in biological fluids.
• Clinical pharmacokinetics attempt to provide both a quantitative relationship between the dose and effect and a framework with which to interpret measurements of drug concentrations in biological fluids.
• The importance of pharmacokinetics in patient care rests on improvement in therapeutic efficacy that can be attained by attention to its principles when dosage regimens are chosen and modified.
![Page 2: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/2.jpg)
2
Clinical Pharmacokinetics (2)
• It is a discipline that use mathematical models to describe and predict drug amounts and concentrations in various body fluids and the change in these quantities overtime.
![Page 3: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/3.jpg)
3
Clinical Pharmacokinetics (3)
Four most important pharmacokineticsparameters that dictate adjustment of dosage in individual patients:• clearance (a measure of the body’s ability to
eliminate drugs); • volume distribution (a measure of the apparent
space in the body available to contain the drug);• elimination half-life ( a measure of rate of
removal of drug from the body); • and bioavailability (the fraction of drug
absorbed as such into the systemic circulation).
![Page 4: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/4.jpg)
4
![Page 5: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/5.jpg)
5
Clearance (1)
• Is defined as that fraction of the apparent volume of distribution is removed in unit of time ml/min/kg
• Indicates the volume of biological fluid that would have to be completely freed of drug to account for elimination
• The total body clearance is usually subdivided into renal and non-renal (hepatic) clearances
![Page 6: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/6.jpg)
6
• The plasma clearance of cephalexin is 4.3 ml/min per kg with 90% of the drug excreted unchanged in the urine. For 60-kg man, the clearance from plasma would be 258/min, with renal clearance accounting for 90% of this elimination. Thus the kidney is able to excrete cephalexin at a rate such that the drug is completely removed (cleared) from approximately 232.2 ml of plasma per minute.
![Page 7: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/7.jpg)
7
Clearance (2)
• Is the most important concept to be considered when a rational regimen for long-term drug administration is to be designed. We want to maintain steady-state concentrations of a drug within a known therapeutic range.
• The steady-state will be achieved when the rate of drug elimination equals the rate of drug administration:
Dosing rate = CL . Css (1-1)• If the steady-state concentration of drug in
blood is known, the rate of drug clearance by the patient will dictate the rate at which the drug should be administered.
![Page 8: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/8.jpg)
8
Clearance (3)
• The clearance of a given drug is constant over the range of concentration encountered clinically, because the absolute rate of drug elimination is essentially a linear function of its plasma concentration.
• It means that the elimination of most drugs follows first order kinetics – a constant fraction of drug is eliminated per unit of time.
![Page 9: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/9.jpg)
9
Clearance (4)
• Drug clearance is similar to creatinine clearance, where the rate of creatinine elimination in the urine is relative to its concentration in plasma.
• Clearance of a drug is its elimination by all routes normalized to the concentration of the drug in biological fluid where measurement can be made:
CL = Rate of elimination/C (1-2)
![Page 10: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/10.jpg)
10
Clearance (5)
• For a single dose of a drug with complete bioavailability (F=100%) and first order kinetic elimination, total systemic clearance may be determined from a mass balance and the integration of equation (1-2) over time:
CL = F.Dose/AUC (1-3) AUC is the total area under the curve that
describes the drug concentration in the systemic circulation as a function of time, from zero to infinity.
![Page 11: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/11.jpg)
11
0 2 4 6 8 10 12 14 16 18
10
20
30
Time (Hours)
Pla
sma
Dru
g C
on
cen
tra
tion
g
/ml
AUC yang dihitung dengan menggunakan rumus luas trapesium (…g/ml x jam)
![Page 12: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/12.jpg)
12
Volume of distribution
• Is defined as the fluid volume that would be required to contain all the drug in the body at the same concentration as in the blood or plasma:
Vd = amount of drug in the body/C (1-4)
• The plasma volume is about 3 L, blood volume is 5.5 L, the extra cellular fluid is 12 L, and the volume of TBW is 42 L for a typical 70 kg man
![Page 13: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/13.jpg)
13
Volume of distribution
• Many drugs exhibit Vd for an excess of those values. For example, if 500 ug of digoxin were in in the body of a 70 kg subject, a plasma conc. Of 0.75 ng would be observed.
• Vd = 500 ug/0.75 ng/ml = 700 L, a value 10 x greater than TBW of 70 kg
• Digoxin distributes preferentially to muscle, adipose tissue and its specific receptor, leaving a very small amount in the plasma.
![Page 14: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/14.jpg)
14
Volume of distribution
• Vd may vary widely depending on pKa, degree of binding to plasma protein, the partition coefficient of the drug in fat, the degree of binding to other tissues, and so forth
• Vd for a given drug can vary according to patient’s age, gender, disease, and the body composition
![Page 15: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/15.jpg)
15
Volume of Distribution
• The Vd in equation (1-4) considers the body as single compartment. In this one-compartment model, all drug administration occurs directly into the central compartment and distribution of drug is instantaneous throughout volume (V).
• Clearance of drug from this compartment occurs in a first order kinetic; that is, the amount of drug eliminated per unit time depends on the amount (concentration) of drug in the body compartment.
![Page 16: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/16.jpg)
16
Kompartemen Perifer
V2
C2
Dosis V1
C1
ke
k21
k12
Model farmakokinetik sistem terbuka dua kompartemen
Kompartemen Sentral
![Page 17: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/17.jpg)
17
Volume of distribution
The decline of plasma concentration with time for a drug introduced into one-compartment model :
Ct = (Dose/Vd) . exp(-kt) (1-5) Ct = C0 . exp(-kt)
k = 0.693/t1/2 (1-6)k = the rate constant for elimination that reflects
the fraction of drug removed from the compartment per unit of time.
The one-compartment model is sufficient to apply to most clinical situation for most drugs
![Page 18: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/18.jpg)
18
0 2 4 6 8 10 12
Time (Hours)
2
4
8
16
32
Pla
sma
Dru
g C
on
cen
tra
tion
g
/ml
t ½
Co
Vd = Dose/Co
The semi-logarithmic plot of plasma concentration vs. time
![Page 19: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/19.jpg)
19
Half-Life (t1/2)
• It is the time it takes for the plasma concentration as the amount of drug in the body to be reduced by 50%.
• It is a derived parameter that changes as a function of both clearance and Vd.
• Relationship between t1/2, clearance, and Vd at steady state is given by:
t1/2 = 0.693. Vss/CL (1-7)
![Page 20: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/20.jpg)
20
Half-life (t1/2)
• CL is the measure of body’s ability to eliminate a drug; as CL decreases due to a disease process, t1/2 would be expected to increase. This reciprocal relation is valid only when the disease does not change Vd.
• T1/2 of diazepam increases with aging; it is not CL that change as a function of age, but the volume of distribution.
![Page 21: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/21.jpg)
21
Bioavailability
• Is defined as the amount of administered drugs which reaches the systemic intact
• It is determined from the relationship between AUC after equivalent IV and PO doses
F (absolute) = AUC after oral dose/AUC after IV dose
F (relative) = AUC after an oral dose of “me-too” product
AUC after an oral dose of original product
![Page 22: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/22.jpg)
22
Pharmacokinetic data available for designing and optimizing dosage regimens• Availability (%)• Urinary excretion (%)• Bound in plasma (%)• Clearance (ml/min/kg/BW)• Volume of distribution (L/kg BW)• Half-life (hours)• Effective concentration (g/ml)• Toxic concentration (g/ml)
![Page 23: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/23.jpg)
23
Examples of pharmacokinetic
calculationThe Vd and clearance of theophylline is 35 L and 3 L/h respectively in a 70 kg person. If the target concentration is 10 ugr/ml, then the loading dose is :Loading dose = Target Cp . Vss/F
= 10 g/ml . 35 L = 350 mg
![Page 24: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/24.jpg)
24
Maintenance dose rate = clearance . concentration
= 3 l/h . 10 mg/l = 30 mg/h = 720 mg/day
Half-life = 0.693 . Vd/CL = 0.693 . 35 L/ 31/h = 8 hours
The expected time to achieve 90 % Css is about 4 half-lives or 32 hours
Examples of pharmacokinetic
calculation
![Page 25: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/25.jpg)
25
![Page 26: Farmakokinetik](https://reader033.vdocuments.mx/reader033/viewer/2022051109/548a20c0b479595b7f8b45bb/html5/thumbnails/26.jpg)
26
Steady-State Drug Concentration
• A steady-state concentration will be achieved when a drug is administered at a constant rate. At this state, drug elimination (the product of clearance and concentration; see equation 1-2) will equal the rate of drug availability.
• This concept also extend to intermittent dosage. During each interdose interval, the concentration of drug rises and falls. Equation 1-1 still applies, but it describes the average drug concentration.
• Average concentration when the steady-state is attained:
Css = F. Dose / (CL . T) (1-8)